Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note published on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Down 2.8 %

NASDAQ BCLI opened at $1.40 on Wednesday. The company has a market cap of $7.98 million, a P/E ratio of -0.29 and a beta of 0.74. The company has a fifty day simple moving average of $1.74 and a 200 day simple moving average of $2.05. Brainstorm Cell Therapeutics has a 12-month low of $1.05 and a 12-month high of $11.25.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.